Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company’s public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
CD8⁺ T cell response in HLA-A*0201 transgenic mice is elicited by epitopes from SARS-CoV S protein

Kai Zhao, Binyin Yang, Yanquan Xu, Changyou Wu

Department of Immunology, Zhongshan School of Medicine, Sun Yat-sen University, 74 Zhongshan 2nd Road, Guangzhou, Guangdong Province 510080, People’s Republic of China

1. Introduction

Severe acute respiratory syndrome (SARS) is an emerging infectious disease caused by a novel coronavirus named as SARS-associated coronavirus (SARS-CoV) which led to thousands of infected patients and hundreds of deaths [1–3]. To date, there is no effective drug to prevent or treat SARS. In addition, there is a possibility of reintroduction of a SARS-like coronavirus into humans and the risk of an escape of SARS-CoV from laboratories [4,5]. Although the outbreaks seem to be over, SARS remains safety concerns [6,7]. SARS-CoV has been isolated and its genome sequenced [8,9]. SARS-CoV is a positive-sense RNA virus that consists of four main structural proteins: spike protein (S), membrane protein (M), envelope protein (E) and nucleocapsid protein (N). S protein is a major structural glycoprotein of SARS-CoV responsible for receptor binding and membrane fusion [10]. It has been reported that vaccines based on the S protein seem to provide protection via an inhibition of viral replication after challenge with live SARS-CoV [11]. In addition, the cell-mediated response induced by S protein also plays a very important role in eliminating virus. We have demonstrated previously that after immunization with SARS-CoV S DNA vaccine, cellular immunity was induced by the evidence of high frequencies of IFN-γ producing effector/memory CD4⁺ and CD8⁺ T cells in mice [12]. Hence, S protein is a major target for developing anti-SARS drugs or vaccines.

Evidence suggests that cytotoxic CD8⁺ T lymphocytes (CTLs) play a pivotal role in the elimination of virus particles during infectious bronchitis virus (IBV) acute infection [13,14]. And to respiratory syncytial virus (RSV) infection, CTLs not only contribute to virus elimination, but also induce immunopathology [15,16]. Excited to us, we found that SARS-CoV S specific CTL responses were detected in patients who had recovered from SARS and mouse model [17,18]. Therefore, CTLs may determine the role of immunity in controlling viral pathogenesis. Human CTLs are specific for peptides presented in the context of major histocompatibility complex (MHC) class I molecules. HLA-A*0201 is expressed as 39–46% of all major ethnicities [19], and furthermore HLA class I alleles have been reported to correlate with SARS susceptibility [20]. Recently, five S
protein-derived CTL epitopes S1042–1050, S787–795, S1167–1175, S958–966 and S411–420 were identified by some groups [21–24]. They have screened HLA-A*0201 restricted peptides which may be appropriate vaccine candidates. However, phenotypic characteristics and functions of the CTLs induced by those HLA-A*0201 restricted peptides remain undefined, and their distributions in different organs are still unknown. In this study, the CD8+ T cell responses induced by HLA-A*0201 restricted peptides were evaluated in draining lymph nodes, spleens and lungs from HLA-A*0201 transgenic mice vaccinated by SARS-CoV S DNA prime and HLA-A*0201 restricted peptides boost strategy. The functionalities and characteristics of the cognate peptides induced CD8+ T cell response were analyzed. Our data confirmed previous reports and demonstrated that numerous powerful peptide-specific CD8+ T cells that represented a memory subset with CD45RBlow and CD62Llow were elicited by HLA-A*0201-restricted peptides both in lymphoid and non-lymphoid tissues. These peptide-specific CD8+ T cells were persisted for over a long period of time, suggesting their long-term protective effect in vivo. These data provide novel information of antigen-specific CD8+ T cell responses in detail, which could be used for design of effective vaccine against SARS-CoV infection in humans.

2. Materials and methods

2.1. Mice

HLA-A*0201/Kb transgenic (Tg) mice were a gift from Prof. Y.Z. Wu (Institute of Immunology, Third Military Medical University, Chongqing, China). Tg mice were bred in a pathogen-free facility. Cell surface HLA-A*0201 expression was assessed by flow cytometry using FITC-labeled anti-human HLA-A2 Ab (BD Biosciences PharMingen). For experimental purposes, six–eight-week-old female mice were used. All experiments were performed according to the guidelines in the Institutional Animal Committee of TMMU.

2.2. SARS-CoV S DNA vaccine

Plasmids encoding SARS-CoV S protein were constructed as described [25] and kindly provided by Dr. Gary J. Nabel from Vaccine Research Center (VRC), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA. Plasmid DNA was purified by plasmid purified kit (QIAGEN, USA). The 260/280 ratios ranged from 1.8 to 2.0. The endotoxin content from purified plasmid DNA was detected below 20 U/ml. The endotoxin level within this range had no effect on the immune response.

2.3. Prediction of epitopes and synthesis of peptides

Sequences of potential HLA-A*0201-binding peptides within SARS-CoV S proteins were based on the B701 strain of SARS-CoV (GenBank accession no. AY278488). We combined two computer algorithms. The first computer-based program was applied with access through the website of Bioinformatics and Molecular Analysis Section (BIMAS) HLA Peptide Binding Predictions [26]. The second algorithm “SYFPEITHI” was developed by Rammensee et al. [27]. Besides, according to the information that several published articles have been reported [21–24], we screened and synthesized five peptides named as P19 (S1042–1050 VVFLHV-2.1. Mice

2.4. Immunization

HLA-A*0201/Kb Tg mice are a well-established model for the study of HLA-A*0201 restricted CTL epitopes and vaccine development [28–30]. Mice were injected intramuscularly with 100 μg truncated SARS CoV S plasmid DNA in 100 μl PBS in thighs. Two weeks later, mice were boosted by subcutaneous injection of HLA-A*0201 restricted peptides (P19–23, 20 μg of each) with 25 μg CpG ODN 1826 (Sangon Crop., Shanghai, China) as adjuvant at the base of tail. PBS was administrated alone as control. Each experiment was repeated 2–3 times with consistent results and 3–12 mice were used in each experiment.

2.5. Media and antibodies

RPMI-1640 media was purchased from Gibco and supplemented with 10% heat-inactivated FCS, 0.1% 2-ME, 100 U/ml penicillin and 100 μg/ml streptomycin. Purified anti-mouse CD28, anti-CD8-FITC, anti-CD8-PE, anti-CD4-PerCP, anti-IFN-γ-APC, anti-IFN-γ-PE, anti-IL-2-PE, anti-TNF-α-APC, anti-CD107a/b-FITC, anti-CD62L-FITC, anti-CD45RB-APC and isotype control Abs were purchased from BD Biosciences PharMingen. RmIL-4 and recombinant murine GM-CSF was obtained from R&D and PEPROTECH, Inc. (USA) respectively. LPS was provided by Sigma (USA).

2.6. Cell culture and measurement of cytokine by ELISA

Mice were sacrificed. Lymph nodes, spleens and lungs from individual mouse were harvested 7–10 d after the boost vaccination. Single-cell suspensions were prepared. Bone marrow derived DCs were generated from Tg mice as previously described with some modification [31]. DCs were pulsed with pool peptides P19–23 (2 μg/ml each peptide) at 37°C for 5 h before co-cultured with lymphocytes. Lymphocyte suspensions from lymph nodes, spleens and lungs were plated respectively in a 96-well micro-titer plate at 4 × 10⁶ cells/200 μl per well in the presence of 2 × 10⁵ peptide-loaded DCs. Supernatants of cell cultures were collected 16 and 72 h later, and levels of IL-2, TNF-α and IFN-γ were assessed respectively by specific ELISA kit (BD PharMingen) according to the manufacturer's protocol.

2.7. ELISPOT assay

Assay was performed using mouse ELISPOT set (BD PharMingen) according to the instruction provided by the manufacturer. Briefly, single-cell suspensions from vaccinated mice were prepared and plated in 96 well micro-plates (Millipore) pre-coated with anti-IFN-γ antibody overnight at 4°C and blocked by RPMI-1640 containing 10% FBS. Cells were incubated for 24 h in the presence or absence of peptide-loaded DCs at 37°C and 5% CO₂. Wells were washed and incubated with biotinylated labeled anti-mouse IFN-γ antibody for 2 h at room temperature. After washing, wells were incubated with streptavidin conjugated horseradish peroxidase for 1 h at room temperature. Wells were extensively washed again, and developed with 3-amin-9-ethyl-carbazole (AEC) substrate solutions. After drying, wells were counted by TEC ELISPOT reader (USA).

2.8. Intracellular cytokine and cell surface staining

Single-cell suspensions from lymph nodes, spleens and lungs of vaccinated mice were co-cultured with or without peptide-loaded DCs for 6 h at 37°C and 5% CO₂. Brefeldin A (10 μg/ml Sigma) was added in the last 5 h incubation. Cells were washed, fixed with
4% paraformaldehyde and permeabilized in PBS buffer containing 0.1% saponin (Sigma), 0.1% BSA and 0.05% NaN₃ overnight at 4 °C. Then cells were stained with conjugated mAbs for surface markers (CD4, CD8, CD62L, CD107a/b and CD45RB) and intracellular cytokines (IFN-γ, IL-2 and TNF-α) for 20 min at 4 °C in dark. Cells were acquired on flow cytometer (BD Calibur) and data were analyzed with the program FlowJo version 6.0 (Treestar, Inc., USA). Isotype controls were included in each staining.

2.9. Statistics

Statistical evaluation of differences between means of experimental groups was performed by analysis of variance and a non-parametric two-tailed t test. A value of P < 0.05 was considered to be significant.

3. Results

3.1. Cellular immune responses were elicited by HLA-A*0201 restricted peptides in both lymphoid and non-lymphoid tissues of immunized Tg mice

To assess the production of cytokines by lymphocytes of Tg mice following SARS-CoV S DNA prime and HLA-A*0201 restricted peptides boost vaccination, HLA-A*0201/Kb Tg mice were randomly divided into three groups to be immunized with cognate DNA plus peptides, DNA alone and PBS as control respectively. 7–10 d after boost vaccination, mice were sacrificed and cells were prepared from lymph nodes, spleens and lungs. The cells were stimulated with or without peptide-loaded DCs to assess HLA-A*0201 restricted peptide-specific immune responses. The levels of IFN-γ, TNF-α and IL-2 were determined by ELISA. However, what percentages of HLA-A*0201 restricted peptide-specific T cells have been induced in Tg mice after DNA plus peptides immunization? Thus, the frequency of IFN-γ-producing cells in total lymphocytes was induced both in lymphoid and non-lymphoid tissues of vaccinated mice with SARS S DNA and HLA-A*0201 peptides. Cultures were set up in triplicate. Each symbol represents one data point from one mouse. *P < 0.05; **P < 0.01; ***P < 0.001; N.S. P > 0.05.

3.2. Frequency of IFN-γ-producing cells from immunized mice following stimulation with HLA-A*0201 restricted peptides

We have detected the production of IFN-γ in total lymphocytes by ELISA. However, what percentages of HLA-A*0201 restricted peptide-specific T cells have been induced in Tg mice after DNA plus peptides immunization? Thus, the frequency of IFN-γ-producing cells at the single cell level was determined by ELISPOT assay. As shown in Fig. 2, 10 d after prime immunization with SARS S DNA and boost immunization with HLA-A*0201 restricted peptides, cells from spleens produced at an average of 124 spots in 4 × 10⁵ cells following stimulation with peptide-loaded DCs. Compared with cells without any peptides stimulation, the specific cells exhibited from 20 to 66-fold increase in the frequency of IFN-γ-producing cells in spleens (P < 0.05). Together, it is believed that HLA-A*0201 restricted peptides P19–23 could act as stimulators to induce a powerful peptide-specific CD8+ T cell immune response.

3.3. IFN-γ-producing cells belong to CD8+ T cells

To directly characterize the subpopulation of IFN-γ-producing cells, we next analyzed the immune responses of T cell subsets induced after prime and boost immunization in Tg mice by FACS. Spleenocytes were stimulated in vitro with or without peptide-loaded DCs in the presence of Brefeldin A. After stimulation for 6 h, the cell-surface markers and intracellular cytokines were stained with anti-CD8, anti-CD4, anti-IFN-γ and isotype controls. For flow cytometric analysis, a lymphocyte-enriched population was initially selected from total cells by forward/side scatter gating (Fig. 3A). Then, the expression of IFN-γ in CD8+ T and CD4+ T subpopulation was analyzed respectively. HLA-A*0201 restricted peptides specific IFN-γ-producing cells were detected in CD8+ T subset but not in CD4+ T cells. These results were consistent with the previous reports [21–24] and identified that the peptides P19–23 were HLA-A*0201 restricted peptides. Based on IFN-γ production, the percentage of peptide-specific CD8+ T cells with peptides stimulation was markedly higher than cells cultured in medium alone (Fig. 3B). These data suggested that P19–23 as HLA-A*0201 restricted peptides could act as stimulators to elicit a striking peptide-specific CTL response.
3.4. Correlation of cytokines produced by HLA-A*0201 restricted peptides specific CTLs

Evidence has confirmed that large amounts of IFN-γ-producing CTLs are induced by peptides P19–23, and furthermore we want to know what kind of other cytokines could be produced by these CTLs. To illuminate this question, splenocytes from prime-boost immunized mice were stimulated in vitro with or without peptide-loaded DCs in the same way as above. The CTL related intracellular cytokines were stained with anti-IFN-γ, anti-TNF-α, anti-IL-2 and isotope controls. Results showed that HLA-A*0201 restricted peptide-specific CTLs could simultaneously produce several kinds of cytokines such as IFN-γ, TNF-α and IL-2 (Fig. 4A). Further analysis of IFN-γ and TNF-α expression demonstrated that peptide-specific CTLs could be divided into three distinct subpopulations, including IFN-γ+, TNF-α− and IL-2− cells, IFN-γ− cells and TNF-α− cells. Most cells expressed both IFN-γ and TNF-α, and only small subsets of the cells expressed either IFN-γ or TNF-α alone (Fig. 4A and B). In the same experiment, the expression of IFN-γ and IL-2 presented the same phenomenon in peptide-specific CTLs which could be separated into IFN-γ+IL-2+ double positive subset, IFN-γ− single positive and IL-2− single positive subsets. Differently, the main subset was composed by IFN-γ+ single positive cells, only a small population of the IFN-γ−IL-2−CD8+ T cells could be detected and very few IL-2−CD8+ T cells were observed (Fig. 4B). Taken together, these results indicated that HLA-A*0201 restricted peptide-specific CTLs elicited in vivo can produce several kinds of cytokines following peptides stimulation, suggesting that the CTLs may have effective function in protecting body against infection.

3.5. Characterization of T cell responses following DNA prime and peptide boost immunization in Tg mice

To characterize the phenotype of HLA-A*0201 restricted peptide-specific CD8+ T cells on the basis of their ability to produce IFN-γ, splenocytes from prime-boost immunized Tg mice were stimulated with peptide-loaded DCs. After 6 h of incubation, cells were harvested, washed and stained for cell-surface markers, including CD45RB as a marker for memory cells in mice and CD62L as effector/memory T subset marker. Cells were first gated on CD8+ T cells and the phenotype of IFN-γ+CD8+ T cells was analyzed. As shown in Fig. 5, nearly 89% of IFN-γ+CD8+ T cells expressed CD45RBlow and approximately 84% subset was CD62Llow. Although most IFN-γ-producing cells were CD45RBlow+CD62Llow cells, a variable fraction (mean value 16%) of the IFN-γ+CD8+ T cells expressed high level of CD62L which were considered as typical central memory CD8+ T cells [32,33]. Thus, on basis of IFN-γ producing cells, a population of peptide-specific CD8+ T cells that have characteristics of memory T cells has been identified in this study. And the IFN-γ+CD8+ T cells with CD45RBlow+CD62Llow might indeed belong to an intermediate sub-
Fig. 4. The correlation of cytokines produced by HLA-A*0201 restricted peptide-specific CD8+ T cells. Tg mice were vaccinated with SARS S DNA and HLA-A*0201 restricted peptides. 10 d after the vaccination, splenocytes were harvested and stimulated with cognate peptides. Then intracellular cytokine staining with flow cytometry was performed. The cells were initially gated at CD8+ T cells. (A) The expression of IL-2, TNF-α and IFN-γ in HLA-A*0201 restricted peptide-specific CD8+ T cells. The number of positive cells was analyzed by flow cytometry and shown in the corner of each panel. The results of one representative assay from four similar independent experiments are shown. (B) Summaries of the independent experiments. The data represents the means of four independent experiments.

Fig. 5. Characteristics of HLA-A*0201 restricted peptide-specific CD8+ T cells. Tg mice were primed with SARS S DNA and boosted with HLA-A*0201 restricted peptides. 10 d after boost vaccination, splenocytes were harvested and stimulated with cognate peptides ex vivo for 6 h. The cells were stained with cell surface anti-CD45RB and anti-CD62L Abs, and then the intracellular cytokine IFN-γ was marked. Based on the expression of IFN-γ, characteristics of HLA-A*0201 restricted peptide-specific CD8+ T cells were analyzed by flow cytometry. (A) The expression of CD45RB and CD62L by IFN-γ+ CD8+ T cells. Representative results are shown from four independent experiments. (B) The data were quantified and presented in a ring chart. Each slice of the ring represents the fraction of the mean value of a given quadrant.
3.6. HLA-A*0201 restricted peptide-specific CD8+ T cells express cytolytic effector molecules

We were interested in determining whether there were a number of cytolytic effector T cells induced by HLA-A*0201 restricted peptides. As we all know, degranulation is a key step to Ag-specific CD8+ T cells to lyze targets cells. Evidence suggests that FACS assay measures the exposure of CD107a/b onto the cell surface as a result of degranulation, presenting in the membrane of cytotoxic granules [34]. We observed a reciprocal expression of surface CD107a/b which may be due to granzyme depletion in cells having undergone recent granule exocytosis. In this study, surface expression of CD107a/b was enriched in CD8+ T cells stimulated by peptides in
The generation of memory CD8+ T cells is a potential strategy in design of vaccine against intracellular pathogens. It has been reported that vaccination with cytotoxic T lymphocyte epitopes could protect against human metapneumovirus infection in murine model [36], suggesting that CTLs play a pivotal role in virus elimination. In this study, the properties of immune responses of CTLs which were induced by SARS S HLA-A*0201 restricted peptides in vaccinated HLA-A*0201 Tg mice were explored. We found that CTLs generated in response to SARS S DNA prime and HLA-A*0201 restricted peptides boost immunization secreted IFN-γ, TNF-α and IL-2. Furthermore, we detected that these CTLs express cell surface CD107a/b for the first time which represent the cytolytic activity of CD8+ T cells in a peptide-specific and HLA-A*0201-restricted manner. Finally, the results showed that the peptide-specific CD8+ T cells that can keep long-term survival in vivo had a memory T cell phenotype based on their low expression of CD62L and high level of CD45RB, and the distributions of them in lymphoid tissues and non-lymphoid tissues were different.

Spike protein is a major structural glycoprotein of SARS-CoV. An understanding of the immunology of coronavirus infections in mice and swine indicated that, of the large number of potential vaccine antigens encoded by the SARS-CoV genome, S glycoprotein would be the best [37]. Recent work has shed light on the important role of S protein in inducing effective cellular immune responses and humoral responses both in mice [12,25] and humans [17].
In our previous studies, we have demonstrated that prime-boost vaccination of mice with SARS-CoV S DNA vaccine induced remarkable antigen-specific cellular and humoral immune responses in response to a pool of entire overlapping S peptides [12]. In view of the advantages of polypeptide vaccine, many teams are trying to identify SARS S epitopes to provide optimum candidates for vaccine development. We have identified two novel epitopes which could induce antigen-specific CD4+ T cell and CD8+ T cell immune responses in BALB/C mice, respectively [18]. However, it is known that the ultimate purpose of scientific research is used by human beings. Although many antigen-specific CD8+ T cell epitopes in SARS-CoV had been identified in animal models, it is not appropriated to directly apply them to the human vaccine. So identification of functional dominant CD8+ T cell epitopes in SARS-CoV S protein for human is crucial. Excited to us is that several HLA-A*0201 restricted peptides from SARS S protein have been screened by some groups currently [21–24]. However, the mechanisms and properties of immune responses induced by these epitopes are still not well understood. In present study, we verified their results and determined the functions and features of peptide-specific CD8+ T cells elicited by these HLA-A*0201 restricted peptides.

Consist with the previous reports [35] which the expression of IFN-γ in lungs is higher than lymph nodes and spleens, suggesting that the effector T cells were transiently endowed with the ability to traffic to non-lymphoid organs. In addition to IFN-γ, these antigen-stimulated CD8+ T cells acquire antiviral effector functions, such as the ability to produce TNF-α, TNF-α that has important effect role in activating macrophages, inducing apoptosis of infected cells and contributing to granuloma formation. IL-2 has little direct effect function but is an indicator of cells with higher capacity for survival and proliferation that can later evolve effect responses. Although peptide-specific CD8+ T cells from both lymph nodes and spleens could produce IL-2 upon peptides stimulation, the level of IL-2 in lungs was undetectable. As we know antigen-specific CD8+ T cells become exhausted by loss of a subset of effect functions and IL-2 production appears most sensitive to inactivation, followed by TNF-α synthesis, while IFN-γ production appears more resistant to this early functional loss [33]. To say in other words, CD8+ T cells producing IL-2 are also more likely to differentiate into memory cells, and CD8+ T cells producing only IFN-γ tend to be short-lived. Thus, we presumed that antigen-activated CD8+ T cells that migrate from lymphoid tissues to lungs which belong to effect organ were short-lived, while most memory CD8+ T cells reside in the lymphoid tissues.

In addition to their potential importance as cytokine-producing T cells, HLA-A*0201 restricted peptide-specific CD8+ T cells were identified based on their ability to express CD107a/b. CD107a and CD107b are two intracellular proteins that are normally found in the cell surface of CTLs [38,39]. Thus, the expression of CD107a/b can actually reflect the cytotoxic ability of antigen-specific CD8+ T cells [34]. Kamath et al. [38] have detected the level of CD107a/b in antigen-specific CD8+ T cells during mycobacterium tuberculosis infection. However, the expression of CD107a/b of antigen-specific CD8+ T cells in SARS has never been detected. Our results showed for the first time that the expression of CD107a/b in peptides stimulated lymphocytes from spleens markedly increased, suggesting the production of cytotoxic antigen-specific CD8+ T cells in vaccinated Tg mice. Meanwhile, we detected the co-expression of IFN-γ with CD107a/b, and TNF-α with CD107a/b respectively. Interestingly, the data demonstrated that a population of CD107a/b+CD8+ T cells that did not produce IFN-γ or TNF-α could be observed (Fig. 6B). These data imply that measuring CD8+ T cell responses by IFN-γ production alone in previous studies may underestimate the total responses and the variety of antigen-specific CD8+ T cells in vivo.

Based on the production of IFN-γ and the expression of CD107a/b, we found that the greater frequencies of IFN-γ+ and CD107a/b+ peptide-specific CD8+ T cells localized in lungs which were the major target site of SARS in humans, whereas secondly in spleens. The frequency of peptide-specific CD8+ T cell in lymph nodes was lower than that in spleens, which was at a low but detectable level (Fig. 7). These data consist with the previous reports, which indicated in hepatitis B virus mouse models at each time point, the greatest frequency of specific CD8+ T cells was found in the liver, although the spleen had the largest number of antigen-specific CD8+ T cells [40]. Thus, it would be of value to determine after immunization whether there is any phenotypic or functional difference between antigen-specific memory CD8+ T cells in the lymphoid and non-lymphoid tissue, as is the case during viral infection.

Besides, we investigated the phenotype of peptide-specific CD8+ T cells based on IFN-γ production. CD45 expression is frequently used to define memory T cells. CD45RB expression was decreased on effector T cells compared to naive T cells, whereas most memory cells, like naive T cells, expressed a CD45RB high phenotype [41]. In this study, the expression of CD45RB molecule was high on the most of IFN-γ producing CD8+ T cells. The presence of this naive phenotype on CD8+ T cells after antigen exposure has already been observed and could be explained by a re-expression after a down-regulation during the effector phase [42,43]. CD62L, a surface protein that mediates homing to lymphoid organs, is reversible in vivo as already described [41,42]. In fact, TCM express relatively high levels of CD62L and TCM express relatively low levels of this molecule. We observed rather 84% of a population of IFN-γCD8+ T cells with CD62Llow and 16% of central memory IFN-γCD8+ T cells with CD62Lhigh. These results are similar with the founding by Meraldi V who demonstrated most of multimer+ CD8+ T cells had intermediate phenotype CD44high, CD45RBhigh and CD62Llow induced by polypeptide from plasmidium berghhei, which might be ready to be conscripted into the effector population during reinfection [43].

To conclude, it has been shown that HLA-A*0201 restricted SARS S epitope-specific CD8+ T cells could protect body against viral infection in Tg mice model. Such protection is mediated by both cytolytic that represent by the expression of CD107a/b and non-cytolytic mechanisms, the latter as a result of IFN-γ, TNF-α and IL-2 production by CD8+ T cells. The distribution of peptide-specific CD8+ T cells which has memory T cell characteristics is different in lymphoid tissues and non-lymphoid tissues. Taken together, these data provided some novel information in cellular immune responses of SARS S antigen-specific CD8+ T cells, which were important in the development of vaccine against SARS-CoV infection. Therefore, we have a hypothesis that SARS S DNA prime and HLA-A*0201 restricted peptides boost vaccine may offer considerable potential in humans, both for preventative vaccines and for past exposure prophylaxis.

Acknowledgments

We are grateful to Drs. Gary J. Nabel, VRC, NIAID, NIH, USA for kindly providing us with SARS CoV S DNA plasmid. We thank Prof. Yuzhang Wu, Institute of Immunology, Third Military Medical University, Chongqing, China, for his kind presents of HLA-A*0201/Ko transgenic mice. We also want to thank Erxia Shen from Department of Immunology, Guangzhou Medical University, Guangzhou,
China, for her help in mouse immunization. This work was sup-
ported by grants from National “863” Project (No. 2007AA022415). 
Conflict of interest statement: The authors have no conflicts of
interest.

References
[1] Ksiazek TG, Erdman D, Goldsmith CS, Zaki SR, Peret T, Emery S, et al. A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med 2003;348(20):1953–66.
[2] Drosten C, Gunther S, Preiser W, van der Werf S, Brodt HR, Becker S, et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med 2003;348(20):1967–76.
[3] Peiris JS, Lai ST, Poon LL, Guan Y, Yam LY, Lim W, et al. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet 2003;361(9366):1139–21.
[4] Normolle D. Infectious diseases. Mounting lab accidents raise SARS fears. Science 2004;304(5671):659–61.
[5] Orellana C. Laboratory-acquired SARS raises worries on biosafety. Lancet Infect Dis 2004;4(2):64.
[6] Fleck F. SARS virus returns to China as scientists race to find effective vaccine. Bull World Health Organ 2004;82(2):152–3.
[7] Paterson R. SARS returns to China. Lancet Infect Dis 2004;4(2):64.
[8] Rota PA, Oberste MS, Monroe SS, Nix WA, Campanelli R, Icenogle JP, et al. Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science 2003;300(5624):1334–9.
[9] Marra MA, Jones SJ, Astell CR, Holt RA, Brooks-Wilson A, Butterfield YS, et al. The genome sequence of the SARS-associated coronavirus. Science 2003;300(5624):1399–404.
[10] Hofmann H, Hattmann K, Marzi A, Grambert T, Geier M, Krummbiegel M, et al. S protein of severe acute respiratory syndrome coronavirus mediates entry into heptoma cell lines and is targeted by neutralizing antibodies in infected patients. J Virol 2004;78(12):6134–42.
[11] Buchholz UJ, Bukreyev A, Yang L, Lamirande EW, Murphy BR, Subbarao K, et al. Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity. Proc Natl Acad Sci U S A 2004;101(26):9806–9.
[12] Huang J, Ma R, Wu CY. Immunization with SARS-CoV S DNA vaccine generates memory CD4+ and CD8+ T cell immune responses. Vaccine 2006;24(23):4905–13.
[13] Pei J, Briels WE, Collisson EW. Memory T cells protect chicks from acute infectious bronchitis virus infection. Virology 2003;306(2):376–84.
[14] See SH, Wang L, Smith R, Collisson EW. The carboxyl-terminal 120-residue polypeptide of infectious bronchitis virus nucleocapsid induces cytotoxic T lymphocytes and protects chickens from acute infection. J Virol 1999;71(10):7889–94.
[15] Ostler T, Davidson W, EhI S. Virus clearance and immunopathology by CD8(+) T cells during infection with respiratory syncytial virus are mediated by IFN-gamma. Eur J Immunol 2002;32(8):2117–23.
[16] Ostler T, EhI S. Pulmonary T cells induced by respiratory syncytial virus are functional and can make an important contribution to long-lived protective immunity. Eur J Immunol 2002;32(9):2562–9.
[17] Yang LT, Peng H, Zhu XL, Li G, Huang ZT, Zhao ZX, et al. Long-lived effector/memory T-cell responses to severe acute respiratory syndrome coronavirus (SARS-CoV) S antigen in recovered SARS patients. Clin Immunol 2006;120(2):171–8.
[18] Huang J, Gao Y, Du J, Bu X, Ma R, Wu C. Priming with SARS CoV S DNA and boosting with SARS CoV S peptides specific for CD4+ and CD8+ T cells promote cellular immune responses. Vaccine 2007;25(39–40):6981–91.
[19] Sidney J, Grey HM, Kubo RT, Sette A. Practical, biochemical and evolutionary implications of the discovery of HLA class I supermotifs. Immunol Today 1999;16(7):261–6.
[20] Lin M, Tseng HK, Trejaut JA, Lee HL, Loo JH, Chu CC, et al. Association of HLA class I with severe acute respiratory syndrome coronavirus infection. BMC Med Genet 2003;4:9.
[21] Tsao YP, Lin JY, Jan JT, Leng CH, Chu CC, Yang YC, et al. HLA-A*0201 restricted T-cell epitopes in severe acute respiratory syndrome (SARS) coronavirus nucleocapsid and spike proteins. Biochem Biophys Res Commun 2006;344(1):63–71.
[22] Wang B, Chen H, Jiang X, Zhang M, Wan T, Li N, et al. Identification of an HLA-A*0201-restricted CD8+ T-cell epitope SSP-1 of SARS-CoV spike protein. Blood 2004;104(1):200–6.
[23] Lv Y, Ruan Z, Wang L, Ni B, Wu Y. Identification of a novel conserved HLA-A*0201-restricted epitope from the spike protein of SARS-CoV. BMC Immunol 2009;10:61.
[24] Zhou M, Xu D, Li X, Li H, Shan M, Tang J, et al. Screening and identification of severe acute respiratory syndrome-associated coronavirus-specific CTL epitopes. J Immunol 2006;177(4):2138–45.
[25] Yang ZY, Kong WP, Huang Y, Roberts A, Murphy BR, Subbarao K, et al. A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice. Nature 2004;428(6982):561–4.
[26] Taylor R. Bioinformatics and molecular analysis section (BIMAS) HLA peptide binding predictions http://bimas.dccn.nih.gov/molbio/hla_bind/index.htm; 2004.
[27] Rammensee H, Bachmann J, Emmerich NP, Bachor OA, Stevanovic S. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 1999;50(3–4):213–9.
[28] Passoni L, Scardino A, Bertazzoli C, Gallo A, Coluccia AM, Lemmonier FA, et al. As a novel lymphoma-associated tumor antigen: identification of 2 HLA-A2.1-restricted CD8+ T-cell epitopes. Blood 2002;99(6):2100–6.
[29] Lishoka GY, Fikes J, Hermanson G, Livingston B, Crimi C, Qin M, et al. Utilization of MHC class I transgenic mice for development of migenine DNA vaccines encoding multiple HLA-restricted CTL epitopes. J Immunol 1999;162(7):3915–23.
[30] Arichi T, Saito T, Major ME, Belayakov IM, Shirai M, Engelhard VH, et al. Prophylactic DNA vaccine for hepatitis C virus (HCV) infection: HCV-specific cytotoxic T lymphocyte induction and protection from HCV-recombinant vaccine infection in an HLA-A2.1 transgenic mouse model. Proc Natl Acad Sci U S A 2000;97(12):297–302.
[31] Cao X, Zhang W, He L, Xie Z, Ma S, Tao Q, et al. Lymphocytosis gene-modified bone marrow dendritic cells act as more potent adjuvants for peptide delivery to induce specific antitumor immunity. J Immunol 1998;161(11):6238–44.
[32] Berenzon D, Schwenk RJ, Letellier L, Guebre-Xabier M, Williams J, Krysch U. Protracted protection to Plasmodium berghei malaria is linked to functionally and phenotypically heterogeneous liver memory CD8+ T cells. J Immunol 2003;171(4):2024–34.
[33] Wherry EJ, Ahmed R. Memory CD8 T cell differentiation during viral infection. J Virol 2004;78(11):5535–45.
[34] Betts MR, Brenchley JM, Price DA, De Rosa SC, Dosek DC, Roederer M, et al. Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. J Immunol Methods 2003;281(1–2):65–78.
[35] Masopust D, Verhey J, Usherwood EJ, Cauley LS, Olson S, Marzo AL, et al. Activated primary and memory CD8 T cells migrate to nonlymphoid tissues regardless of site of activation or tissue of origin. J Immunol 2004;172(8):4875–82.
[36] Herd KA, Mahalingam S, Mackay IM, Nissen M, Sloots TP, Tindall RW. Cytotoxic T-lymphocyte epitope vaccine protects against human metapneumovirus infection and disease in mice. J Virol 2006;80(4):2034–44.
[37] Johnston RE. A candidate vaccine for severe acute respiratory syndrome. N Engl J Med 2004;351(8):827–8.
[38] Kamath A, Woodworth JS, Behar SM. Antigen-specific CD8+ T cells and the development of central memory during Mycobacterium tuberculosis infection. J Immunol 2006;177(9):6361–9.
[39] Wieland T, Baier A, Losinger F, Kunstmann E, Seifert C, et al. Protective immunity against dengue virus infection in rhesus macaques. J Virol 2007;81(20):11157–66.
[40] Qu D, Lanier G, Yuan ZH, Wen YM, Howard CR, Ahmed R. Localization of CD8+ cells specific for hepatitis B virus surface protein in the liver of immunized mice. J Med Virol 2008;80(2):819–24.
[41] trees for different stages of an in vivo immune response. J Immunol 1995;155(2):743–51.
[42] Meraldi V, Romero JF, Kensil C, Corradin G. A strong CD8+ T cell response is elicited by the synthetic polypeptide from the C-terminus of the circumsporozoite protein of Plasmodium berghei together with the adjuvant QS-21: quantitative and phenotypic comparison with the vaccine model of irradiated sporozoites. Vaccine 2005;23(21):2801–12.